Pathology Handbook

 New search
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # ALL

PLEASE NOTE: Recent changes have been made to this Test


 Recent changes for Chromogranin A

Recent changes for Chromogranin A
DateFieldChanged FromChanged To
15th March 2024
Collection & Request Instructions

Ideally, CgA should be measured in a fasting state. 

Proton pump inhibitor (PPI) therapy should be ceased at least 2 weeks prior if possible.

Proton pump inhibitor (PPI) therapy should be ceased at least 2 weeks prior if possible.

15th March 2024
Collection & Request Instructions

Ideally, CgA should be measured in a fasting state. 

Proton pump inhibitor (PPI) therapy should be ceased at least 2 weeks prior if possible.

8th December 2023
Volume (Adults)

1 mL

Minimum/Paediatric Volume

1 mL

Preferred Specimen Type

Serum

Blood

Chromogranin A

Laboratory:Clinical Biochemistry
Test Code:CHROMOG A
Specimen Types:Blood
Container Types:
SST
Adults Volume or Mass:1 mL
Minimum/Paediatric Volume or Mass:1 mL
Collection & Request Instructions:Fast for > 8 hours pre procedure
Collect on Ice

Proton pump inhibitor (PPI) therapy should be ceased at least 2 weeks prior if possible.

Transport Instructions between Sites and/or Laboratories:On Ice
Send to lab immediately

Please indicate medications and supply clinical notes.

Transport frozen

Assay Frequency:Weekly
External Laboratory:Peter MacCallum Cancer Centre (VCCC)
Additional Notes:

Reference Interval: 27 - 94 ug/L  ( M and F)

New method Cisbio CgA from 12/5/2014.

Note: Correlation with the previous Dako CgA method. Cisbio CgA results are higher and quite different from the Dako method - no conversion factor.

Peter MacCallum Cancer Centre(VCCC)- BIochemistry laboratory 85595406

 

Interpretation:

Serum Chromogranin A (CgA) is the most established neuroendocrine neoplasm (NEN) marker for diagnosis in high risk populations, monitoring progression or treatment response. Test performance is better with advanced than localised disease, higher disease burden and with tumours of gastroenteropancreatic origin.

Non-NEN causes of CgA elevation include: renal failure, atrophic gastritis, liver impairment, cardiac failure, inflammatory bowel disease, PPI or histamine type-2 receptor antagonist therapy, and other non-neuroendocrine tumours.

Correlation with disease progression may be lost during treatment with somatostatin analogues as these significantly reduce CgA synthesis and release from tumour cells but may not indicate a reduction in tumour mass.

For patients being monitored, serial CgA should be measured using the same assay. 

References:

1. COSA consensus guidelines for the diagnosis and management of neuroendocrine neoplasms (2022)

2. Up-to-Date. Accessed 15/03/2024